Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aptose Biosciences ( (TSE:APS) ) has issued an update.
On August 22, 2025, Aptose Biosciences held its reconvened Annual and Special Meeting where shareholders approved the appointment of Ernst & Young LLP as the new independent registered public accounting firm. Additionally, Aptose received a US$1.5 million advance from Hanmi Pharmaceutical, part of an existing loan agreement, to support the ongoing development of its lead drug, tuspetinib, for AML treatment.
The most recent analyst rating on (TSE:APS) stock is a Buy with a C$6.00 price target. To see the full list of analyst forecasts on Aptose Biosciences stock, see the TSE:APS Stock Forecast page.
Spark’s Take on TSE:APS Stock
According to Spark, TipRanks’ AI Analyst, TSE:APS is a Underperform.
Aptose Biosciences faces significant financial distress with no revenue generation and substantial losses. The negative technical indicators and valuation metrics further highlight the stock’s weak position. However, recent corporate events provide a glimmer of hope with potential advancements in AML treatment and strategic partnerships, slightly mitigating the overall risks. The stock remains risky, requiring cautious optimism for future developments.
To see Spark’s full report on TSE:APS stock, click here.
More about Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology. Their lead product, tuspetinib, is an oral kinase inhibitor being developed for acute myeloid leukemia (AML) treatment.
YTD Price Performance: -83.79%
Average Trading Volume: 7,050
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$4.03M
Find detailed analytics on APS stock on TipRanks’ Stock Analysis page.